JPRN-UMIN000012484招募中2 期
Sorafenib vs. half dose Sorafenib and UFT combined therapy in patients with Hepatocellular carcinoma refractory to TACE: Randamized Prospective Study - Sorafenib vs. half dose Sorafenib and UFT combined therapy in patients with Hepatocellular carcinoma refractory to TACE: Randamized Prospective Study
Hanshin Association of Molecular Targeted Therapy for HCC0 个研究点目标入组 50 人开始时间: 2013年12月9日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Vascular invasion 2) Obstruction in the hepatic artery 3) Sever complication such as belows a.cardiac failure b.renal failure c.active infection (except for viral hepatitis) d.active bleeing in gastrointestinal tract e.active other cancer f.Hepatic encepharopathy or severe Mental disorder 4)High fever more than 38 degrees C 5)Not only pregnant or lacting women, but women with suspected pregnancy 6)Inappropriate patients for this study judged by physicians
研究者
相似试验
进行中（未招募）
1 期
Sorafenib in combination with local micro-therapy guided by Gd-EOB-DTPA (Primovist) enhanced MRI in patients with inoperable liver cancer (SORAMIC)EUCTR2009-012576-27-PLMedical Faculty, University Magdeburg710
进行中（未招募）
1 期
Evaluation of Sorafenib in combination with local micro-therapy guided by Gd-EOB-DTPA enhanced MRI in patients with inoperable hepatocellular carcinoma - SORAMICCarcinoma hepatocelular (CHC)Patients with Hepatocellular carcinoma (liver-predominant disease)MedDRA version: 12.1Level: LLTClassification code 10019828Term: Hepatocellular carcinoma non-resectableMedDRA version: 12.1Level: LLTClassification code 10019829Term: Hepatocellular carcinoma recurrentMedDRA version: 12.1Level: LLTClassification code 10019830Term: Hepatocellular carcinoma resectableMedDRA version: 12.1Level: LLTClassification code 10049010Term: Carcinoma hepatocellularEUCTR2009-012576-27-SIMedical Faculty, University Magdeburg665
进行中（未招募）
1 期
Sorafenib in combination with local micro-therapy guided by Gd-EOB-DTPA (Primovist) enhanced MRI in patients with inoperable liver cancer (SORAMIC)EUCTR2009-012576-27-ATMedical Faculty, University Magdeburg710
进行中（未招募）
1 期
Sorafenib in combination with local micro-therapy guided by Gd-EOB-DTPA (Primovist) enhanced MRI in patients with inoperable liver cancer (SORAMIC)Patients with Hepatocellular carcinoma (liver-predominant disease)MedDRA version: 16.1 Level: LLT Classification code 10019829 Term: Hepatocellular carcinoma recurrent System Organ Class: 100000004864MedDRA version: 16.1 Level: LLT Classification code 10049010 Term: Carcinoma hepatocellular System Organ Class: 100000004864MedDRA version: 16.1 Level: LLT Classification code 10019828 Term: Hepatocellular carcinoma non-resectable System Organ Class: 100000004864MedDRA version: 16.1 Level: LLT Classification code 10019830 Term: Hepatocellular carcinoma resectable System Organ Class: 100000004864EUCTR2009-012576-27-NLMedical Faculty, University Magdeburg665
进行中（未招募）
不适用
Sorafenib in combination with local micro-therapy guided by Gd-EOB-DTPA (Primovist) enhanced MRI in patients with inoperable liver cancer (SORAMIC)Patients with Hepatocellular carcinoma (liver-predominant disease)MedDRA version: 18.0Level: LLTClassification code 10019829Term: Hepatocellular carcinoma recurrentSystem Organ Class: 100000004864MedDRA version: 18.0Level: LLTClassification code 10019828Term: Hepatocellular carcinoma non-resectableSystem Organ Class: 100000004864MedDRA version: 18.0Level: LLTClassification code 10049010Term: Carcinoma hepatocellularSystem Organ Class: 100000004864MedDRA version: 18.0Level: LLTClassification code 10019830Term: Hepatocellular carcinoma resectableSystem Organ Class: 100000004864EUCTR2009-012576-27-BEMedical Faculty, University Magdeburg710